Compare Inovio Pharmaceuticals Inc (INO) vs US Global Jets ETF (JETS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs US Global Jets ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $1.1 (market cap $112.19M), while US Global Jets ETF trades at $27.16 (market cap $878.48M). The key difference: US Global Jets ETF is far larger — about 7.8× Inovio Pharmaceuticals Inc's market cap, and US Global Jets ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and US Global Jets ETF for 26 Days on average.
| INO | JETS | |
|---|---|---|
Market Cap | $112.19M | $878.48M |
Volume | 3,201,278 | 4,465,925 |
Sector | Health | Sector/Thematic |
52-Week High | $2.65 | $33.53 |
52-Week Low | $0.66 | $23.64 |
Typical Hold Time | 43 Days | 26 Days |
Enterprise Value | $83.51M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals (INO) trades at $1.155, up 2.21% today, while showing bearish technical signals with negative cash flow and substantial losses. The company's financials reveal minimal revenue of $65,340 against an $84.95 million net loss in 2025, with profitability metrics deeply negative. However, analyst sentiment is optimistic with a 58.83% buy rating and $2.75 consensus price target, driven by the upcoming FDA decision on INO-3107 for recurrent respiratory papillomatosis by October 30, 2026.
INO presents high-risk speculation with potential for significant upside if FDA approval is secured, but carries substantial fundamental weaknesses including persistent cash burn and negative margins. Investors should weigh the binary outcome of the regulatory decision against the company's challenging financial position and technical bearishness.
JETS (U.S. Global Jets ETF) trades at $27.67, down 1.53% with a bearish technical outlook. The ETF faces headwinds from rising fuel costs and geopolitical tensions impacting airline profitability. Technical indicators show strong bearish momentum with moving averages signaling sell pressure, though RSI suggests potential oversold conditions. Recent news highlights competitive pressure from defense-focused aerospace ETFs that have outperformed JETS on total returns.
The outlook remains challenging with fuel cost volatility and competitive ETF alternatives presenting risks. However, oversold technical conditions and potential travel demand recovery offer selective opportunities for investors seeking airline exposure. Key catalysts include fuel price stabilization and holiday travel trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About US Global Jets ETF
JETS provides targeted exposure to the global airline industry, including commercial airlines, aircraft manufacturers, and airport operators. It focuses on major U.S. and international carriers like Delta, United, and American Airlines.
Read more on JETS →
